Estrella Immunopharma (Estrella Immunopharma) Cash And Cash Equivalents : $4.73 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Cash And Cash Equivalents?

Estrella Immunopharma's quarterly cash and cash equivalents declined from Sep. 2023 ($22.14 Mil) to Dec. 2023 ($9.05 Mil) but then stayed the same from Dec. 2023 ($9.05 Mil) to Mar. 2024 ($4.73 Mil).

Estrella Immunopharma Cash And Cash Equivalents Historical Data

The historical data trend for Estrella Immunopharma's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma Cash And Cash Equivalents Chart

Estrella Immunopharma Annual Data

Trend

Jun21

Cash And Cash Equivalents

Estrella Immunopharma Quarterly Data
	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial					2.88	-	22.14	9.05	4.73

Estrella Immunopharma Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Estrella Immunopharma (NAS:ESLAW) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Estrella Immunopharma Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Estrella Immunopharma (Estrella Immunopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLAW) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

ESLA:USA

Address

5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608

Website

https://www.estrellabio.com

Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma (Estrella Immunopharma) Headlines

No Headlines